Loading candles…
Wanbury Ltd, incorporated in 1988 and headquartered in Navi Mumbai, India, operates as a vertically integrated pharmaceutical company. It engages in research, manufacturing, and exporting activities within the pharmaceutical industry, focusing on Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations. The company serves markets in India and over 50 countries worldwide. Wanbury holds a significant market share in products such as Metformin and Sertraline and has obtained regulatory approvals from agencies including the USFDA and EU-GMP. Its business model emphasizes being a preferred partner for global pharmaceutical companies. The company does not list any subsidiaries or key management details publicly.
This page is a live market overview for WANBURY LIMITED (WANBURY) on the NSE. As a listed security, WANBURY LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for WANBURY before placing trades on tick2trade.
As of the latest feed, WANBURY last traded at ₹227.3 on NSE, up ₹2.15 (0.95%) from the previous close of ₹225.15. Today's session range is ₹226.45 – ₹234.25, against a 52-week band of ₹161.5 – ₹358.85. Traded volume today stands at 8.69K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for WANBURY in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether WANBURY is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for WANBURY LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in WANBURY. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated WANBURY option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 11 Aug 2026 |
| Results - FY26 | WANBURY : 29-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 14, 2026 has been re-scheduled. Further, the Company ha… | 29 May 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 14 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 4 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 15 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.